Christopher Drinjak

Christopher specialises in assisting lawyers to enhance their skills, win new instructions, manage client relationships and augment their international networks.

He has worked in senior business development roles based in the UK and in Germany, and currently is the business development lead for the firm's Life Sciences & Healthcare industry sector.

CV

Since 2019 Senior business development manager (Life sciences and healthcare), and Senior business development manager (Disputes and investigations, IP, Commercial tech and data, and Patents), Taylor Wessing

2011 - 2018 Senior practice development manager, Industry development (Global financial institutions group), and Interim head of business development Germany, Latham & Watkins

2001 - 2011 Business development manager (Finance and capital markets), Head of London L&DR business development, and Business development manager (Litigation and dispute resolution), Clifford Chance

Carrière

2011 - 2018 Senior practice development manager, Industry development (Global financial institutions group), and Interim head of business development Germany, Latham & Watkins

2001 - 2011 Business development manager (Finance and capital markets), Head of London L&DR business development, and Business development manager (Litigation and dispute resolution), Clifford Chance

Formation

2001 Masters of business administration, International University, Germany

1996 M.A. in musicology, Michigan State University, US

1994 B.A. in German and B.A. in Music Performance, Michigan State University, US

Christopher Drinjak

Expertise

Secteurs

CV

Carrière

Formation

Langues étrangères

Rendez-vous à

Christopher Drinjak

Expertise

Secteurs

CV

Carrière

Formation

Langues étrangères

Related news & insights

Unpacking the Dutch Leadiant cases: a legal battle with significant implications for the pharmaceutical industry

New product liability risks for AI products

The regulation of clinical trials in which AI is deployed

Data privacy in AI due diligence

Selecting your AIA notified body

Purpose limitation and data minimisation: key considerations for AI training in the life sciences sector

Re-use of patient data in scientific research to train AI systems - important GDPR considerations

UK approach to regulating AI in Life Sciences

The UPC: a new rocket docket for life sciences patent litigation

Navigating IP in AI due diligence

Autres avocats qui pourraient vous intéresser

Rendez-vous à